High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons

Journal of Public Health Management and Practice : JPHMP
Kristine M SchmitSarah Bur

Abstract

Correctional facilities provide unique opportunities to diagnose and treat persons with latent tuberculosis infection (LTBI). Studies have shown that 12 weekly doses of isoniazid and rifapentine (INH-RPT) to treat LTBI resulted in high completion rates with good tolerability. To evaluate completion rates and clinical signs or reported symptoms associated with discontinuation of 12 weekly doses of INH-RPT for LTBI treatment. During July 2012 to February 2015, 7 Federal Bureau of Prisons facilities participated in an assessment of 12 weekly doses of INH-RPT for LTBI treatment among 463 inmates. Fisher exact test was used to assess the associations between patient sociodemographic characteristics and clinical signs or symptoms with discontinuation of treatment. Of 463 inmates treated with INH-RPT, 424 (92%) completed treatment. Reasons for discontinuation of treatment for 39 (8%) inmates included the following: 17 (44%) signs/symptoms, 9 (23%) transfer or release, 8 (21%) treatment refusal, and 5 (13%) provider error. A total of 229 (49.5%) inmates reported experiencing at least 1 sign or symptom during treatment; most frequently reported were fatigue (16%), nausea (13%), and abdominal pain (7%). Among these 229 inmates, signs/sym...Continue Reading

References

Dec 13, 1993·Archives of Internal Medicine·A R PelletierC L Woodley
Feb 1, 1997·American Journal of Respiratory and Critical Care Medicine·F ChavesJ H Bates
Feb 1, 1997·American Journal of Public Health·D T KooG W Rutherford
Jun 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C R MacIntyreN M Graham
Mar 10, 1998·American Journal of Public Health·J P TulskyG Schecter
Mar 27, 2003·American Journal of Preventive Medicine·Mark N LobatoPatricia M Simone
Oct 26, 2005·American Journal of Preventive Medicine·Mary C WhiteL Masae Kawamura
Jan 5, 2011·PLoS Medicine·Iacopo BaussanoFabio Scano
Dec 14, 2011·The New England Journal of Medicine·Timothy R SterlingUNKNOWN TB Trials Consortium PREVENT TB Study Team
Mar 14, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·H A A Al-DarrajiF L Altice
Aug 12, 2015·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·E E Bliven-SizemoreUNKNOWN TB Trials Consortium
Feb 13, 2016·American Journal of Respiratory and Critical Care Medicine·James D MancusoTzu-Cheg Kao
Sep 16, 2016·American Journal of Public Health·Lauren A LambertMaryam B Haddad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Related Papers

The New England Journal of Medicine
T R SterlingTB Trials Consortium PREVENT TB Study Team
The New England Journal of Medicine
Mehdi Mirsaeidi
The New England Journal of Medicine
James R Johnson
© 2022 Meta ULC. All rights reserved